The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia

Cairo University (CU)

Status: Unknown

Conditions: Preeclampsia

Treatments: Drug: MgSO4

Study type: Interventional

Funder types: Other

Identifiers

NCT03891498

53

Details and patient eligibility

About

100 women with severe preeclanpsia received Magnesium sulfate 6 grams intravenous over 20 minutes as a loading dose. Resistance index [RI], pulsatility index [PI] and systolic/diastolic [S/D] ratio of the umbilical artery, uterine aryery and fetal middle cerebral artery before and repeated 20 minutes after intravenous administration of 6 grams of magnesium sulphate (loading dose) over 20 minutes . fetal breathing movements and fetal gross movements are counted within 20 minutes, before and after intravenous administration of 6 grams of magnesium sulphate (loading dose) over 20 minutes

Full description

100 women with severe preeclanpsia received Magnesium sulfate 6 grams intravenous over 20 minutes as a loading dose. Resistance index [RI], pulsatility index [PI] and systolic/diastolic [S/D] ratio of the umbilical artery, uterine aryery and fetal middle cerebral artery before and repeated 20 minutes after intravenous administration of 6 grams of magnesium sulphate (loading dose) over 20 minutes . fetal breathing movements and fetal gross movements are counted within 20 minutes, before and after intravenous administration of 6 grams of magnesium sulphate (loading dose) over 20 minutes

Enrollment: 100 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Singleton pregnancy.

• Primigravida or Multigravida.

• Pregnant females ≥ 37 weeks of gestation.

• Diagnosed as severe preeclampsia by the following criteria:

  • Sustained systolic blood pressure of ≥160 mmHg or a sustained diastolic blood pressure of ≥ 110 mmHg.
  • Proteinuria measured as +1 or more by dipstick or 24 hours urine collection with proteinuria ≥ 0.3 grams.
  • Oliguria or creatinine > 1.1 mg%.
  • Laboratory findings characteristic of HELLP syndrome.
  • Symptoms suggestive of severe preeclampsia ; severe headache, blurring of vision, epigastric pain.

Exclusion criteria

• Multifetal pregnancy.
• History of epilepsy.
• Patients with diabetes.
• Patients with renal disease.
• Fetuses with congenital anomalies.
• Patients receiving anticoagulants e.g. heparin (unfractionated or low molecular weight).
• Patients with severe IUGR.
• Patients with accidental hemorrhage.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

MgSO4

Experimental group

Description:

The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.

Treatment:

Drug: MgSO4